Head-to-head evidence
CKD-703 vs Tepotinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: MET · full Non-Small Cell Lung Cancer pipeline
CKD-703
Developed by Chong Kun Dang Pharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2029 · NCT07439094 (registry estimate)
Tepotinib · Tepmetko
Marketed by Merck KGaA and partners
NCT02864992 · Phase 2 · active, not recruiting
An open-label, single-arm Phase 2 study with no comparator arm; objective response was assessed by blinded independent review. The response rate (46% in 99 patients with at least 9 months of follow-up) supported FDA accelerated approval, but without a control group the study cannot separate the drug's effect from the course of the disease.
Next expected readout: December 2027 · NCT06083857 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CKD-703's landscape · Tepotinib's landscape